# Clinical Cancer Research
## Table of Contents

### Highlights of This Issue 3097

#### SPECIAL FEATURES

#### CCR 20th Anniversary Commentary

3099  **CCR 20th Anniversary Commentary: Chimeric Antigen Receptors—From Model T to the Tesla**

Patrick Hwu

#### CCR Translations

3102  **Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy**

Zachary A. Cooper, Alexandre Reuben, Jacob Austin-Breneman, and Jennifer A. Wargo

3105  **Growth Factor Receptor Fusions Predict Therapeutic Sensitivity**

Manmeet S. Ahluwalia and Jeremy N. Rich

#### Molecular Pathways

3108  **Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy**

Diletta Di Mitri, Alberto Toso, and Andrea Alimonti

#### Reviews

3113  **Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy**

Atsushi Yonezawa, Suparna Dutt, Cariad Chester, Jeewon Kim, and Holbrook E. Kohrt

3121  **Nanotechnology: Future of Oncotherapy**

Kshipra M. Gharpure, Sherry Y. Wu, Chun Li, Gabriel Lopez-Berestein, and Anil K. Sood

#### CANCER THERAPY: CLINICAL

3131  **Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning**

Muriel Hannon, Yves Beguin, Grégory Eux, Sophie Servais, Laurence Seidel, Carlos Graux, Johan Maertens, Tessa Kerre, Coline Daunile, Muriel de Bock, Marianne Fillet, Aurélie Ory, Evelyne Willems, André Godhot, Stéphanie Humblets-Baron, and Frédéric Baron

3140  **PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients**


3149  **Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases**


3159  **Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma**

Jennifer R. Brown, Matthew S. Davids, Jordi Rodon, Pau Abrisquet, Siddha N. Kasar, Joanne Lager, Jason Jiang, Coumaran Egile, and Farukhi T. Awan

3169  **Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate–Treated Castration-Resistant Prostate Cancer Patients**

Xu S. Xu, Charles J. Ryan, Kim Stuyckens, Matthew R. Smith, Fred Saad, Thomas W. Griffin, Youn C. Park, Margaret K. Yu, An Vermeulen, Italo Poggesi, and Partha Nandy

3178  **Biologic Activity of Autologous, Granulocyte–Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines**

John M. Goldberg, David E. Fisher, George D. Demetri, Donna Neuberg, Stephen A. Allsop, Catia Fonseca, Yukoh Nakazaki, David Nemser, Chandrajit P. Raut, Suzanne George, Jeffrey A. Morgan, Andrew J. Wagner, Gordon J. Freeman, Jerome Ritz, Cecilia Lezcano, Martin Mihm, Christine Canning, F. Stephen Hodi, and Glenn Dranoff

### PERSONALIZED MEDICINE AND IMAGING

3187  **Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children’s Oncology Group**

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
Tony Mok, Yi-Long Wu, Jin Soo Lee, Chong-Jen Yu, Vitoire Sritrungroong, Jennifer Sandoval-Tan, Guia Ladrera, Sumitra Thongprasert, Vichien Srimuninnimit, Meilin Liao, Yunzhong Zhou, Caicun Zhou, Fatima Fuerte, Benjamin Margono, Wei Wen, Julie Tsai, Matt Truman, Barbara Klughammer, David S. Shames, and Lin Wu

Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas
Misu Lee, Tobias Wiedemann, Claudia Gross, Ines Leinhäuser, Federico Roncaroli, Rickmer Braren, and Natalia S. Pellegrata

Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma

HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL
Robbie Carson, Basak Celikci, Cathy Fenning, Arman Javadi, Nyree Crawford, Lucia Perez-Carbonell, Mark Lawler, Daniel B. Longley, Patrick G. Johnston, and Sandra Van Schaeybroeck

An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies
Jyoti Asundi, Lisa Crocker, Jarrod Tremayne, Peter Chang, Chie Sakakana, Josh Tanguay, Susan Spencer, Sreedevi Chalasani, Elizabeth Luis, Karen Gascoigne, Rupal Desai, Rajiv Raja, Brad A. Friedman, Peter M. Haventy, Paul Polakis, and Ron Firestein

Targeting Glutamine Metabolism in Breast Cancer with Aminoxyacetate
Preethi Korangath, Wei Wen Teo, Helen Sadik, Liangfeng Han, Noriko Mori, Charlotte M. Huijts, Honee Wildes, Santosh Bharti, Zhe Zhang, Cesar A. Santa-Maria, Hualing Tsai, Chi V. Dang, Vered Stearns, Zaver M. Bhujwalla, and Sarawati Sukumar

The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor Microenvironment

A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
Shang-Fan Yu, Bing Zheng, MaryAnn Go, Jeff Lau, Susan Spencer, Helga Raab, Robert Sotiano, Suchit Jhunjhunwala, Robert Cohen, Michele Caruso, Paul Polakis, John Flygare, and Andrew G. Polson

Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma
Anna Luisa Di Stefano, Alessandra Fucci, Veronique Frattini, Marianne Labussiere, Karina Mokhtari, Pietro Zoppoli, Yannick Marie, Aurelie Bruno, Blandine Boiselier, Marine Giry, Julien Savatovsky, Mehdi Touat, Hayat Belaid, Aurelie Kamoun, Ahmed Idbaih, Caroline Houillier, Feng R. Luo, Jean-Charles Soria, Josep Tabernero, Marica Eoli, Rosina Paterra, Stephen Yip, Kevin Petecca, Jennifer A. Chan, Gaetano Finocchiaro, Anna Lasorella, Marc Sanson, and Antonio Javarone
See related commentary, p. 3105

Head-to-Head Comparison and Evaluation of 92 Plasma Protein Biomarkers for Early Detection of Colorectal Cancer in a True Screening Setting
Hongda Chen, Manuela Zucknick, Simone Werner, Phillip Knebel, and Hermann Brenner
### Table of Contents

**3327** Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment

**3340** Genetic Modulation of Neurocognitive Function in Glioma Patients
Yanhong Liu, Renke Zhou, Erik P. Sulman, Michael E. Scheurer, Nicholas Boehler, Georgina N. Armstrong, Spiridon Tsavachidis, Fu-Wen Liang, Carol J. Etzel, Charles A. Conrad, Mark R. Gilbert, Terri S. Armstrong, Melissa L. Bondy, and Jeffrey S. Wefel

**3347** POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer

### Corrections

**3356** Correction: Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers

**3358** Correction: A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma

**3359** Correction: CTLA4 Blockade Broadens the Peripheral T-cell Receptor Repertoire

### About the Cover

The heatmap shows expression of immune-related genes in endometrial cancers from the TCGA series. POLE proofreading-mutant tumors display evidence of a robust cytotoxic T-cell response. For details, see the article by van Gool and colleagues on page 3347 of this issue.